| 000 | 01553 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250518041109.0 | ||
| 264 | 0 | _c20200709 | |
| 008 | 202007s 0 0 eng d | ||
| 022 | _a1879-1484 | ||
| 024 | 7 |
_a10.1016/j.atherosclerosis.2019.05.003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPérez de Isla, Leopoldo | |
| 245 | 0 | 0 |
_aPotential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. _h[electronic resource] |
| 260 |
_bAtherosclerosis _c07 2019 |
||
| 300 |
_a40-45 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 |
_aCholesterol, LDL _xblood |
| 650 | 0 | 4 | _aHeterozygote |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperlipoproteinemia Type II _xblood |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 | _aMathematical Concepts |
| 650 | 0 | 4 |
_aProprotein Convertase 9 _ximmunology |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 700 | 1 | _aRay, Kausik K | |
| 700 | 1 | _aWatts, Gerald F | |
| 700 | 1 | _aSantos, Raul D | |
| 700 | 1 | _aAlonso, Rodrigo | |
| 700 | 1 | _aMuñiz-Grijalvo, Ovidio | |
| 700 | 1 | _aDiaz-Diaz, Jose Luis | |
| 700 | 1 | _aBadimon, Lina | |
| 700 | 1 | _aCatapano, Alberico L | |
| 700 | 1 | _aMata, Pedro | |
| 773 | 0 |
_tAtherosclerosis _gvol. 286 _gp. 40-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.atherosclerosis.2019.05.003 _zAvailable from publisher's website |
| 999 |
_c29701885 _d29701885 |
||